<code id='DCDF431B2F'></code><style id='DCDF431B2F'></style>
    • <acronym id='DCDF431B2F'></acronym>
      <center id='DCDF431B2F'><center id='DCDF431B2F'><tfoot id='DCDF431B2F'></tfoot></center><abbr id='DCDF431B2F'><dir id='DCDF431B2F'><tfoot id='DCDF431B2F'></tfoot><noframes id='DCDF431B2F'>

    • <optgroup id='DCDF431B2F'><strike id='DCDF431B2F'><sup id='DCDF431B2F'></sup></strike><code id='DCDF431B2F'></code></optgroup>
        1. <b id='DCDF431B2F'><label id='DCDF431B2F'><select id='DCDF431B2F'><dt id='DCDF431B2F'><span id='DCDF431B2F'></span></dt></select></label></b><u id='DCDF431B2F'></u>
          <i id='DCDF431B2F'><strike id='DCDF431B2F'><tt id='DCDF431B2F'><pre id='DCDF431B2F'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:11925
          Checkpoint inhibitor
          Adobe

          ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

          The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

          advertisement

          iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Malaria cases in Florida and Texas: Here’s what you need to know
          Malaria cases in Florida and Texas: Here’s what you need to know

          MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.